Online Pharmacy US

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus’s Qnexa (the phentermine/topiramate combination) will earn Decision Resources’ propriet ary clinical gold standard in 2013 and through 2018 following its anticipated U.S. approval for the disease in 2011. Qnexa has competitive advantages in efficacy — it provides nearly double the (more…)

The objective of this study was to describe the applicability and the dropout of the pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer.Psychiatrists treated major depressive disorder in advanced cancer patients on the basis of the algorithm. For discussing the problems related to the algorithm, we reviewed the reasons for the non-application of the algorithm and the reasons for dropout of patients (more…)

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus’s Qnexa (the phentermine/topiramate combination) will earn Decision Resources’ proprietary clinical gold standard in 2013 and through 2018 following its anticipated U.S. approval for the dis ease in 2011… (Source: Obesity / Weight Loss / Fitness News From Medical News Today)

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has completed the enrollment in its Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R) alprazolam) in patients with panic disorder. AZ-002 is an inhalation product candidate being developed for the acute treatment of panic attacks associated with panic disorder. AZ-002 is being developed through Symphony Allegro, a development collaboration formed between Alexza and (more…)

AlexzaPharmaceuticals, Inc. ( Nasdaq: ALXA) announced today that it has initiateda Phase IIa clinical trial with AZ-002 (Staccato(TM) alprazolam) inpatients with panic disorder. AZ-002 is an inhalation product candidatebeing developed for the acute treatment of panic attacks associated withpanic disorder. The Phase IIa clinical trial is an in-clinic proof of concept study. [click link for full article] (Source: Mental Health News From Medical (more…)

The objective of this study was to assess the effectiveness and efficacy of benzodiazepines in the treatment of GAD based on trial drop-out rates. We used a systematic review of randomized controlled trials that compared any of the thr ee best established benzodiazepines (diazepam, Lorazepam and aLprazolam) against placebo. Our primary outcome for effectiveness was withdrawal for any reason. Our secondary (more…)

Conclusions: These results suggest that although alprazolam did not improve the THI score or sensation level of loudness significantly, it has a desirable effect on VAS. Further work is needed to determine the beneficial effects of alprazolam in distressed or depressed patients. (Source: Medical Science Monitor)

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus’s Qnexa (the phentermine/topiramate combination) will ea rn Decision Resources’ proprietary clinical gold standard in 2013 and through 2018 following its anticipated U.S. approval for the disease in 2011. Qnexa has competitive advantages in efficacy — it provides nearly double the (more…)

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus’s Qnexa (the phentermine/topiramate combination) will earn Decision Resources’ proprietary clinical gold standard in 2013 and throu gh 2018 following its anticipated U.S. approval for the disease in 2011… (Source: Obesity / Weight Loss / Fitness News From Medical News Today)

Conclusions: These results suggest that although alprazolam did not improve the THI score or sensation level of loudness significantly, it has a desirable effect on VAS. Further work is needed to determine the beneficial effects of alprazolam in distressed or depressed patients. (Source: Medical Science Monitor)